Market Overview

Vetr Crowd Downgrades Celgene


The Vetr community on Monday downgraded Celgene Corporation (NASDAQ: CELG) from 4.5 stars (Strong Buy) to 4 stars (Buy). Crowd confidence was very bullish, with 100 percent of the Vetr community reporting a Buy position on the stock.

See how crowdsourced ratings could help you time the market

This upgrade came with news that Celgene would be acquiring Juno Therapeutics Inc (NASDAQ: JUNO) for $9 billion in an effort to expand its cancer treatment efforts.

Despite the downgrade, the Vetr crowd remained bullish, setting a target price of $114.80, which sits well above the current share price of $102.94. Analysts were equally as bullish, with most recent estimates sitting in the $120-$160 range.

Posted-In: VetrDowngrades Analyst Ratings


Related Articles (CELG + JUNO)

View Comments and Join the Discussion!

Latest Ratings

INTCMorgan StanleyUpgrades0.0
SOEvercore ISI GroupUpgrades0.0
ADBEDZ BankDowngrades0.0
AVGOCowen & Co.Downgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Vetr Community Upgrades Teva Pharmaceuticals

Netflix's Big Q4 Beat Pushes Stock To New Highs, Plans To Spend Nearly $8 Billion On Content In Q1